Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A1 | P13866 | 5/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | DCUN1D1 | Q96GG9 | 7/20 | 0.38 |
| ▸ | UBE2M | P61081 | 6/20 | 0.38 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.38 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.37 |
| ▸ | RAF1 | P04049 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.36 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.36 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776434 | 0.95 | PTGER3 (0.39) | SLC5A1FYNDCUN1D1UBE2MEPHB4 | |
| SCHEMBL16776479 | 0.90 | SLC5A1 (0.41) | SLC5A1FYNEPHB4RAF1BRAF | |
| SCHEMBL16776417 | 0.89 | SMN1; SMN2 (0.38) | FYNDCUN1D1UBE2MEPHB4RAF1 | |
| SCHEMBL16776418 | 0.88 | RXFP1 (0.37) | FYNDCUN1D1UBE2MEPHB4RAF1 | |
| SCHEMBL16776472 | 0.87 | CA2 (0.41) | SLC5A1FYNEPHB4RAF1BRAF | |
| SCHEMBL16776419 | 0.85 | BRAF (0.40) | FYNEPHB4RAF1BRAFCA2 | |
| SCHEMBL16776355 | 0.85 | CA2 (0.41) | SLC5A1FYNCA2CA9 | |
| SCHEMBL16776294 | 0.85 | RHOA (0.48) | FYNRAF1BRAF | |
| SCHEMBL16776423 | 0.84 | SMN1; SMN2 (0.48) | FYNRAF1BRAFCA2CA9 | |
| SCHEMBL16776292 | 0.83 | SMN1; SMN2 (0.39) | SLC5A1FYNEPHB4RAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | SLC5A1 1202/4885FYN 2694/4885DCUN1D1 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.